Imunon, Inc. - Common Stock IMNN 深 滬
已收盤 08-01 16:00:00 美东时间
8.50
+0.210
+2.53%
華盛通- 最 高8.6963
- 今 開8.155
- 成交量 10.74万股
- 最 低 8.01
- 昨 收 8.29
- 總市值 1.73亿
- 52周最高 47.40
- 市盈率 靜 --
- 換手率 0.53%
- 52周最低 5.55
- 委 比 -49.93%
- 總股本 2031.95万
- 歷史最高 29736.00
- 量 比 0.16
- 振 幅 8.28%
- 歷史最低 5.55
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IMUNON (IMNN) Stock Is Trending Wednesday: What's Going On?
Shares of IMUNON are trading higher Wednesday morning. The company announced a clinical milestone for its lead drug candidate, IMNN-001.
07-30 23:48
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
IMUNON Inc. announced the initiation of its pivotal Phase 3 OVATION 3 Study for IMNN-001, a DNA-mediated immunotherapy, in women with newly diagnosed advanced ovarian cancer. The first patient has been dosed, marking a significant milestone. IMNN-001 has shown promising results in earlier trials, improving overall survival and reducing recurrence rates. The Phase 3 trial will assess its safety and efficacy compared to standard chemotherapy. IMUNO...
07-30 12:05
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
IMUNON Inc., a clinical-stage biotechnology company, announces a conference call on August 5, 2025, at 11:00 a.m. ET to discuss second-quarter 2025 financial results and provide updates on its IMNN-001 clinical development program, a DNA-based interleukin-12 immunotherapy for advanced ovarian cancer in a Phase 3 trial. Participation details and webcast links are provided. IMUNON focuses on non-viral DNA technology for innovative cancer treatments...
07-29 12:30
Imunon Announces 15% Stock Dividend Approval
Imunon ( ($IMNN) ) just unveiled an announcement. On July 28, 2025, IMUNON, Inc...
07-28 20:28
IMUNON Announces Stock Dividend Boosting Shareholder Value
IMUNON, Inc. (Nasdaq: IMNN) announced a 15% stock dividend (0.15 shares per share) reflecting its confidence in its Phase 3 clinical programs, long-term growth strategy, and commitment to shareholders. The dividend, totaling approximately 448,000 shares, will be distributed on August 21, 2025, to shareholders of record as of August 7, 2025. CEO Stacy R. Lindborg highlighted the company's dedication to creating value through innovative therapies, ...
07-28 12:05
Imunon, Inc. Advances DNA Vaccine Study for COVID-19 Variants
Imunon, Inc. (($IMNN)) announced an update on their ongoing clinical study. Imu...
07-26 00:32
Imunon shares are trading lower after the company announced a 1-for-15 reverse stock split.
Imunon shares are trading lower after the company announced a 1-for-15 reverse ...
07-23 20:30
IMUNON Announces 1-For-15 Reverse Stock Split, Effective July 25, 2025
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock split of its issued and outstanding common stock, par value $0.01 per share,
07-23 20:09
IMUNON announces reverse stock split
IMUNON (NASDAQ:IMNN) on Wednesday announced a reverse stock split of its issued and outstanding common stock, par value $0.01 per share, at a ratio of one share of common stock for every fifteen share...
07-23 20:07
Imunon Registers Additional Shares to Raise Capital
Imunon ( ($IMNN) ) just unveiled an update. On July 22, 2025, Imunon, Inc. file...
07-22 20:27
